New order on the US market for IQool™ System

BrainCool AB (publ) has received its first order of IQool™ in the state of New Mexico, USA.

The hospital in question has placed an order of two IQool™ Systems with a corresponding order value of approximately USD 60.000.

US VP Sales and support Troy Van Der Veur comments: 

— The order, placed without previous evaluation by the hospital, is a clear sign of the acceptance of the product, its evidence and performance on other US sites. The first order in New Mexico paves the way for further business in the state.

We expect to implement the product in Utah and other states in the Western part of the US throughout 2020.

CEO Martin Waleij comments: 

We welcome Troy as our new VP, and his ability to lead by example in developing the business in the US.

— The first objective of 2020 is to close orders on the sites where product evaluations have taken place in 2019, where we experienced strong user feedback and where budget allocations have been made for capital for this year.

— The clinical performance of the product makes orders like the one in New Mexico possible, where BrainCool replaces the main competitor in clinical practice without any need for further evaluation of the product.

For more information

Martin Waleij - CEO                                                               
+46 - 733 -93 70 76                                                                                          
E-mail: martin.waleij@braincool.se                       

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.